Escalon® Medical Corp. to Introduce Sonomed Escalon VuPad™ at Annual Meeting of the American Academy of Ophthalmology PR Newswire ARDMORE, Pa., Nov. 14, 2013 ARDMORE, Pa., Nov. 14, 2013 /PRNewswire/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced its plans to introduce a new tablet-based ultrasound imaging system, the Sonomed Escalon VuPad™, at the upcoming 117th Annual Meeting of the American Academy of Ophthalmology (AAO) November 16-19^th at the Ernest N. Morial Convention Center in New Orleans. The product will be featured at the Sonomed Escalon booth 1316. The VuPad™ offers A-scan, B-scan, and/or UBM modalities in a sleek, tablet-like package. Key features include portable ergonomic design, elegant user interface, wireless interconnectivity to EMR's, image management systems, and printers, multi-touch ultra high resolution touch screen with pinch zoom functionality, and most notably, outstanding image quality and measurement accuracy. Chief Executive Officer, Richard J. DePiano Jr. commented, "We are excited to introduce the VuPad™, the latest in portable ultrasound technology. Its upcoming launch, along with the VuMAX® HD introduced earlier this calendar year, demonstrates the Company's continued focus on developing and delivering new best-in-class ophthalmic ultrasound solutions." The Company anticipates shipments of VuPad™ systems as early as the end of the calendar year following clearance from FDA and other regulatory bodies. For additional information about the AAO visit http://www.aao.org/meetings/annual_meeting/. About Escalon Medical Founded in 1987, Escalon Medical Corp. (NASDAQ: ESMC) specializes in the development, marketing and distribution of ophthalmic diagnostic imaging and surgical products branded under the Sonomed Escalon name.Products include a variety of ophthalmic ultrasound, digital imaging and photography, and image management systems as well as surgical products including intraocular gases, fiber optic light guides and sources, and other surgical vitreoretinal instruments. The Company seeks to grow its ophthalmic business by further developing and diversifying its product offering through internal development programs, strategic partnerships, and the acquisition of technology so as to best leverage the Company's distribution capabilities. The Company has headquarters in Ardmore, Pennsylvania and research and development, manufacturing and distribution operations in Lake Success, New York, New Berlin, Wisconsin and Stoneham, Massachusetts. For additional information visit www.escalonmed.com and www.sonomedescalon.com Forward Looking Statements This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to: implement its growth and marketing strategies, improve upon the operations of the Company including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance; grow our remaining ophthalmic business unit; improve our financial position; implement cost reductions; generate cash; and identify, finance and enter into business relationships and acquisitions. Other factors include uncertainties and risks related to: new product development, commercialization, manufacturing and market acceptance of new products; marketing acceptance of existing products in new markets; research and development activities, including failure to demonstrate clinical efficacy; delays by regulatory authorities, scientific and technical advances by the Company or third parties; introduction of competitive products; ability to reduce staffing and other costs and retain benefit of prior reductions; third party reimbursement and physician training, and general economic conditions. Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10- K for year ended June 30, 2013, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources. SOURCE Escalon Medical Corp. Website: http://www.escalonmed.com Contact: Richard J. DePiano, Jr., President and CEO, 610-688-6830; Alison Ziegler, Cameron Associates, 212-554-5469
Escalon® Medical Corp. to Introduce Sonomed Escalon VuPad™ at Annual Meeting of the American Academy of Ophthalmology
Press spacebar to pause and continue. Press esc to stop.